ACTOS Teleseminar

Text Size

ACTOS Teleseminar 

On-Demand CLE

You can purchase this seminar to watch through online streaming and downloading or on hard copy discs. Share with your office and build your firm's resource library. Recordings may be accepted for MCLE credit in your state. Visit AAJ's online audio and video provider Playback Now »


For additional assistance
Please call 800.241.7785

Not an AAJ Member?

Join today to have access to all of the Legal Education AAJ has to offer!

September 8, 2011

Search the AAJ Exchange for materials from this education program »

Mounting concerns over Actos safety
For almost 10 years, worldwide concerns have escalated regarding the serious complications and side effects pioglitazone may cause:

  • 2002: The FDA begins a ten-year epidemiological study designed to evaluate the risk of bladder cancer associated with the use of this drug.
  • 2007: The FDA issues a “black box” warning about the serious risk of adverse cardiovascular events, including heart attack, heart failure, and cardiovascular-related deaths.
  • August 2011: The FDA informs the public that it updated Actos drug labels to include safety information regarding the increases risk of bladder cancer.
  • Actos is now banned in both France and Germany.  The European Medicines Agency (EMA) issued warnings about the increased cancer risk.

Moderator Instructions
   W. Roger Smith, III, AL

History of Actos 
   Hunter J. Shkolnik, NY

Recent Studies and Regulatory Action
   Dawn M. Chmielewski, OH

Status of Current Litigation
   Richard J. Arsenault, LA

Venue Considerations
   Stacy K. Hauer, MN

Questions and Answers


The American Association for Justice
777 6th Street, NW, Ste 200 • Washington, DC  20001 • 800.424.2725 or 202.965.3500

© 2014 AAJ